Osimertinib, a third‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI), is the standard of care for EGFR mutation‐positive non‐small cell lung cancer (NSCLC). This evidence concerns the gene EGFR and lung cancer.